MAIA Biotechnology, Inc.

Company Snapshot: MAIA Biotechnology, Inc.

Last Change Volume High Low

Company Overview

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.

Client News

  1. Nov 17 2023 MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
  2. Nov 17 2023 MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
  3. Nov 15 2023 MAIA Biotechnology Announces $4 Million Registered Direct Offering
  4. Nov 10 2023 FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma